drugset / Trial / NCT05260411
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.
Timeline
- Start
- 2022-01-26
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK102 | Monoclonal antibody | 450 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 600 mg | Subcutaneous |